Sign In
Buy CE
$45.24
+1.35 (+3.08%)
At Close: Aug 04, 2026
Celanese (CE) Gets ISCC-Certified for Low Carbon CCU Methanol
12:11pm, Monday, 25'th Mar 2024
Celanese (CE) now offers low-carbon choices to customers across its Acetyl Chain and Engineered Materials products under the ECO-CC name.
Celanese (CE) and Secarna Partner for Antisense Therapies
08:16am, Friday, 22'nd Mar 2024
Celanese's (CE) collaboration with Secarna enables the development of a novel implant with the potential to significantly alter how disease-modifying ASO treatments are given.
Why Is Celanese (CE) Up 10% Since Last Earnings Report?
12:36pm, Thursday, 21'st Mar 2024
Celanese (CE) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Hold Onto Celanese (CE) Stock For Now
11:41am, Thursday, 21'st Mar 2024
While Celanese (CE) faces headwinds from demand softness and pricing pressures, it gains on strategic acquisitions and productivity measures.
Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
09:55am, Wednesday, 20'th Mar 2024
DALLAS, TX and MARTINSRIED, GERMANY / ACCESSWIRE / March 20, 2024 / Celanese Corporation (NYSE:CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a lead
Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
09:00am, Wednesday, 20'th Mar 2024
DALLAS & MARTINSRIED, Germany--(BUSINESS WIRE)---- $CE--Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies.
Celanese: Appetite For Acquisitions Remains
08:36pm, Sunday, 10'th Mar 2024
Celanese's acquisition of DuPont's Mobility and Materials division did not bring the expected returns due to a challenging market environment. The company is currently saddled with a large debt and de
Celanese (CE) Announces Commercial Launch of Glaukos' iDose TR
07:15am, Monday, 04'th Mar 2024
iDose TR uses Celanese's (CE) VitalDose EVA. It is approved following the completion of two pivotal trials which demonstrates safety and efficacy.
7 Earnings Losers With a Shot at a Strong Comeback
12:27pm, Thursday, 22'nd Feb 2024
While companies who rank among the earnings losers category don't obviously generate confidence, it's also important to keep in mind the big picture. Technology juggernaut Nvidia (NASDAQ: NVDA ) provi
Celanese Corporation (CE) Q4 2023 Earnings Call Transcript
01:56pm, Wednesday, 21'st Feb 2024
Celanese Corporation (CE) Q4 2023 Earnings Call Transcript
Celanese's (CE) Earnings and Revenues Miss Estimates in Q4
09:46am, Wednesday, 21'st Feb 2024
Pricing of Celanese's (CE) Engineered Material segment declines in Q4 due to tough competition and product mix challenges in the Americas and Europe.
Celanese (CE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
07:30pm, Tuesday, 20'th Feb 2024
While the top- and bottom-line numbers for Celanese (CE) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare
Celanese (CE) Q4 Earnings and Revenues Miss Estimates
06:30pm, Tuesday, 20'th Feb 2024
Celanese (CE) came out with quarterly earnings of $2.24 per share, missing the Zacks Consensus Estimate of $2.29 per share. This compares to earnings of $1.44 per share a year ago.
CE or BCPC: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 20'th Feb 2024
Investors interested in stocks from the Chemical - Specialty sector have probably already heard of Celanese (CE) and Blachem (BCPC). But which of these two stocks is more attractive to value investors
Countdown to Celanese (CE) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
10:21am, Wednesday, 14'th Feb 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Celanese (CE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua
